Persistence of CD33 expression at relapse in CD33(+) acute myeloid leukaemia patients after receiving Gemtuzumab in the course of the disease

Br J Haematol. 2008 Dec;143(5):744-6. doi: 10.1111/j.1365-2141.2008.07153.x.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aminoglycosides / therapeutic use*
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antigens, CD / blood*
  • Antigens, Differentiation, Myelomonocytic / blood*
  • Antineoplastic Agents / therapeutic use*
  • Child, Preschool
  • Drug Therapy, Combination
  • Female
  • Follow-Up Studies
  • Gemtuzumab
  • Humans
  • Leukemia, Myeloid, Acute / drug therapy
  • Leukemia, Myeloid, Acute / immunology*
  • Male
  • Middle Aged
  • Retrospective Studies
  • Sialic Acid Binding Ig-like Lectin 3
  • Young Adult

Substances

  • Aminoglycosides
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antigens, CD
  • Antigens, Differentiation, Myelomonocytic
  • Antineoplastic Agents
  • CD33 protein, human
  • Sialic Acid Binding Ig-like Lectin 3
  • Gemtuzumab